Company / Cash & Equivalents
Biogen Cash & Equivalents History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.9B
FY2019
5-year range
-
FY2016-FY2019
Trend
+137.9%
vs FY2018
Sector context
#13 of 209
Health Care
What the data says
Among 209 Health Care companies, Biogen is in the top 6% for cash & equivalents. Cash & Equivalents returned to growth in FY2019 after 2 years of decline, reaching $2.9B.
Based on SEC 10-K filings.
$2.9B in FY2019 with a 3-year CAGR of +7.8%. Top quartile in the Health Care sector.
Improved from $1.6B to $2.9B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +7.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 209This company $2.9B Sector average $696.0M
▼
+318.6% above sector average
Key checks
Key Insights
- 3-year CAGR of +7.8%, indicating consistent growth.
- In FY2019, cash & equivalents increased 137.9% year-over-year.
- Ranks #13 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $2.9B | +137.9% |
| FY2018 | $1.2B | -22.2% |
| FY2017 | $1.6B | -32.4% |
| FY2016 | $2.3B | +77.9% |
As of FY2019 · SEC 10-K · Updated Mar 3, 2026